Photo of Michael Cecchini taken from medicine.yale.edu
Jun 24, 2024, 22:56
Giovanni Marchegiani: Perioperative modified FOLFIRINOX for pancreas cancer
Giovanni Marchegiani, Pancreas Surgeon at The University of Padua, made the following post on X:
“Perioperative modified FOLFIRINOX for resectable pancreas cancer
- Non randomized trial 46 pts
- 72% underwent surgery
- 12 months PFS 67%
- Postoperative ctDNA positivity was strongly associated with recurrence.”
Syed A. Ahmad, Director at University of Cincinnati Cancer Center & Chief of Surgical Oncology at University of Cincinnati, retweeted the post, adding the following:
“Interesting results. Similar to our SWOG Cancer Research Network 1505 trial with % completing upfront tx, low % of adj, and getting surgery but sig longer mOS (37.2 v. 22.4 mo). Wonder if pts getting surgery off protocol and included in ITT affected results? Will need to read paper.”
Read further.
Source: Giovanni Marchegiani/X and Syed A. Ahmad/X
.
cancer
cancer recurrence
cancer treatment
chemotherapy
ctDNA
Giovanni Marchegiani
Michael Cecchini
modified FOLFIRINOX
OncoDaily
Oncology
oncology research
pancreas cancer
Pancreatic Cancer
perioperative FOLFIRINOX
PFS
resectable pancreas cancer
surgery
surgical oncology
SWOG 1505 trial
SWOG Cancer Research Network
Syed A. Ahmad
University of Cincinnati Cancer Center
University of Padua
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 26, 2024, 15:12
Dec 26, 2024, 15:10
Dec 26, 2024, 15:03
Dec 26, 2024, 15:03
Dec 26, 2024, 14:55
Dec 26, 2024, 14:47
Dec 26, 2024, 14:44